Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

777.25 +4.61 (+0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena ↗
Could Regeneron Pharmaceuticals be the next big winner in biotech? Join us as we break down the company's strengths, challenges, and future potential in this insightful episode. 
Via The Motley Fool
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
Via MarketMinute
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
Is Regeneron a Multimillionaire-Maker Stock? ↗
It's an extremely high bar for any company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study.... 
Via MarketMinute
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates. 
Via The Motley Fool
News headline image
Is Eli Lilly's Weight Loss Empire in Trouble? ↗
It won't be easy to knock the company off its pedestal. 
Via The Motley Fool
News headline image
3 Profitable Stocks We Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making ↗
Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio. 
Via The Motley Fool
Topics Earnings
News headline image
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Underrated Weight Loss Stocks to Buy Now ↗
These companies have a lot more to offer than their prospects in the weight loss market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining dema... 
Via StockStory
News headline image
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Biotech Giants to Buy in 2026 ↗
Both of these players are leaders in their fields. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
From Society For Science
Via GlobeNewswire
News headline image
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years ↗
The pharmaceutical specialist has had strong momentum over the past six months, and that could continue for a while. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗
This player's pipeline should keep growth going over the long run. 
Via The Motley Fool
News headline image
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly... 
Via MarketMinute
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
Via MarketMinute
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only... 
Via StockStory
Topics Stocks
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data
The latest Personal Consumption Expenditures (PCE) price index data has revealed a significant shift in the U.S. inflationary landscape, presenting a complex puzzle for the Federal Reserve. As of early... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.